Sistema de Salut de Catalunya
Institut Català de la Salut
[Garralda E] Research Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Laurie SA] Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada. [Seymour L] Canadian Cancer Trials Group, Queens University, Cancer Centre of South Eastern Ontario, Kingston, ON, Canada. [de Vries EGE] Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
Vall d'Hebron Barcelona Hospital Campus
2023-07-04T06:51:40Z
2023-07-04T06:51:40Z
2023-05-24
Cáncer; Inmunología tumoral
Càncer; Immunologia tumoral
Cancer; Tumour immunology
Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
Article
Versió publicada
Anglès
Càncer - Immunoteràpia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy; DISEASES::Neoplasms; Other subheadings::Other subheadings::/therapy; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::/terapia
Nature Portfolio
Nature Communications;14
https://doi.org/10.1038/s41467-023-38837-3
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
